## **Product Data Sheet**

#### PerCP/Cy5.5 anti-human IL-10

**Catalog # / Size:** 3107090 / 100 tests

3107085 / 25 tests

**Clone:** JES3-9D7 **Isotype:** Rat IgG1, κ

Immunogen: COS - expressed, recombinant human

IL-10

Reactivity: Human

**Preparation:** The antibody was purified by affinity

chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated


antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



LPS-stimulated human peripheral blood mononuclear cells (in the presence of monensin) were surface stained with CD14 APC, fixed, permeabilized, and then stained with IL-10 (clone JES3-9D7) PerCP/Cy5.5 (top) or rat IgG1, κ PerCP/Cy5.5 isotype control

### **Applications:**

**Applications:** Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by intracellular

immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for

optimal performance for each application.

\*PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of

690 nm.

Application Notes:

**ELISA Capture**<sup>1-5</sup> **or ELISPOT Capture**<sup>6</sup>: The purified JES3-9D7 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502) as the detecting antibody and recombinant human IL-10 (Cat. No. 571009) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.

**Neutralization**<sup>1-3,9</sup>: The LEAF<sup>TM</sup> purified antibody (Endotoxin <0.1 EU/ $\mu$ g, Azide-Free, 0.2  $\mu$ m filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. No. 501407). The JES3-9D7 antibody can neutralize the bioactivity of natural or recombinant IL-10.

Additional reported applications (for the relevant formats)

**include:** immunohistochemical staining<sup>12</sup>.

**Note:** For testing human IL-10 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430601 to 430606) are specially developed and recommended. The JES3-9D7 antibody reacts with human and viral interleukin-10 (IL-10).

Application References:

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA Capture, Neut)

2. Gotlieb W, et al. 1992. Cytokine 4:385. (ELISA Capture, Neut)

3. Yssel H, et al. 1992. J. Immunol. 149:2378. (ELISA Capture, Neut)

4. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.

(ELISA Capture)

- 5. Burdin N, et al. 1993. J. Exp. Med. 177:295. (ELISA Capture)
- 6. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISPOT Capture)
- 7. Schaerli P, et al. 2000. J. Exp. Med. 192:1553.
- 8. Jason J, et al. 1999. Clin. Diagn. Lab Immunol. 6:73.
- 9. Akdis CA, et al. 1998. J. Clin. Invest. 102:98. (Neut)
- 10. Stary G, et al. 2011. J. Immunol. 186:103. PubMed
- 11. Mason GM, et al. 2012. PNAS. PubMed
- 12. Smith DR, et al. 1994. Am. J. Pathol. 145:18. (IHC)

#### **Description:**

IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.

# Antigen References:

- 1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
- 2. de Waal-Malefyt R, et al. 1992. Curr. Opin. Immunol. 4:314.
- 3. Howard M, et al. 1992. Immunol. Today. 13:198.